Skip to main content

SkinHealth Systems Inc.

For the period ended Mar 31, 2025. Filed May 8, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 8, 2025

SKIN$15.94-4.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Cash Flows (Unaudited)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

Three Months Ended March 31,
20252024
Cash flows from operating activities:
Net loss$(10,096)$(679)
Adjustments to reconcile net loss to net cash from operating activities
Share-based compensation3,4766,636
Amortization of intangible assets3,1804,985
Depreciation of property and equipment1,8562,773
Amortization of other assets1,128890
Amortization of debt issuance costs786951
Inventory write-down2775,479
Provision for estimated credit losses739656
Change in fair value of warrant liabilities(349)1,464
Gain on repurchase of convertible senior notes, net—(16,087)
Deferred income taxes(265)(1,030)
Other, net(663)3,108
Changes in operating assets and liabilities:
Accounts receivable3,9895,879
Inventories3,761(11,081)
Prepaid expenses, other current assets, and income tax receivable2,9061,936
Accounts payable, accrued expenses, and income tax payable(5,730)(20,786)
Other, net(1,999)(1,948)
Net cash provided by (used for) operating activities2,996(16,854)
Cash flows from investing activities:
Cash paid for intangible assets(1,100)(1,458)
Cash paid for property and equipment(45)(344)
Net cash used for investing activities(1,145)(1,802)
Cash flows from financing activities:
Repurchase of convertible senior notes—(57,750)
Payment of tax withholdings on vested stock awards(250)(868)
Net cash used for financing activities(250)(58,618)
Net change in cash, cash equivalents, and restricted cash1,601(77,274)
Effect of foreign currency translation on cash1,367(1,117)
Cash, cash equivalents, and restricted cash beginning of period370,063523,025
Cash, cash equivalents, and restricted cash end of period$373,031$444,634

The accompanying notes are an integral part of these unaudited financial statements

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.